These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 26287143

  • 1. Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.
    Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, Mokaleng B, Zeevaart JR, Sathekge M.
    Molecules; 2015 Aug 14; 20(8):14860-78. PubMed ID: 26287143
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems.
    Eppard E, Homann T, de la Fuente A, Essler M, Rösch F.
    J Nucl Med; 2017 Mar 14; 58(3):432-437. PubMed ID: 28082433
    [Abstract] [Full Text] [Related]

  • 6. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.
    J Nucl Med; 2016 Apr 14; 57(4):557-62. PubMed ID: 26659347
    [Abstract] [Full Text] [Related]

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr 14; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 8. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2015 Feb 14; 42(2):197-209. PubMed ID: 25411132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM.
    Eur J Nucl Med Mol Imaging; 2013 Apr 14; 40(4):486-95. PubMed ID: 23179945
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
    Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, Schwamborn K, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Mar 14; 57(3):367-71. PubMed ID: 26585062
    [Abstract] [Full Text] [Related]

  • 15. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.
    Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C.
    Clin Nucl Med; 2015 Feb 14; 40(2):e163-6. PubMed ID: 25275415
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun 14; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 18. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
    Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.
    J Nucl Med; 2018 Apr 14; 59(4):625-631. PubMed ID: 28986512
    [Abstract] [Full Text] [Related]

  • 19. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.
    Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, Klutmann S, Beyersdorff D, Budäus L, Wester HJ, Mester J, Bannas P.
    Eur J Nucl Med Mol Imaging; 2017 Apr 14; 44(4):670-677. PubMed ID: 27896369
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.